Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Cecilio Douglas Campbell

General Practice Miami, FL Medical Doctor

NPI 1952849168 CMS profile 3632086

9853 Sw 40Th St, Miami, FL 33165

Open in the dashboard

General payments

$58

3 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$45,692 paid to institutions, not to them · program years 2022–2023

Through program year 2025, Cecilio Douglas Campbell of Miami, FL is reported in the CMS Open Payments database as having received $58 across 3 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $45,692 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 23rd percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24 1
2023 General $14 1
2021 General $19 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cecilio Douglas Campbell
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Cecilio Douglas Campbell were reported at $24. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Cecilio Douglas Campbell General Practice median Middle half National median
2019 $0 $107 $37–$285 $163
2020 $0 $75 $25–$213 $114
2021 $19 $93 $30–$272 $132
2022 $0 $103 $36–$279 $149
2023 $14 $106 $34–$276 $160
2024 $0 $114 $39–$290 $164
2025 $24 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Sumitomo Pharma America, Inc. $24 1 payment
  2. Sanofi-Aventis U.S. LLC $19 1 payment
  3. Phadia US Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $58 3 payments
Products named General payments · program years 2021–2025
  1. GEMTESA $24 1 payment
  2. SOLIQUA 100/33 $19 1 payment
  3. ImmunoCAP $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 210 drugs

Part D claims

27,595

Median for General Practice: 1,105

Drug cost

$775,192

Median for General Practice: $48,734

Branded share of claims

15.2%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dapagliflozin Dapagliflozin Propanediol Brand 257 $130,295
Eliquis Apixaban Brand 144 $80,874
Entresto Sacubitril/Valsartan Brand 75 $48,710
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 289 $39,939
Saxagliptin Hcl Generic 250 $30,861
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 258 $21,215
Tadalafil Generic 188 $17,862
Saxagliptin-Metformin Er Saxagliptin Hcl/Metformin Hcl Brand 44 $17,327
Xarelto Rivaroxaban Brand 28 $15,324
Albuterol Sulfate Hfa Albuterol Sulfate Brand 428 $15,249

The 10 drugs with the highest cost, of 210 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Records

3 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record